Atea Pharmaceuticals, Inc.
AVIR · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $2,419 | $3,440 | $104 |
| Gross Profit | $0 | -$2,419 | -$3,440 | -$104 |
| % Margin | – | – | – | – |
| R&D Expenses | $38,347 | $32,275 | $29,584 | $25,671 |
| G&A Expenses | $7,220 | $9,070 | $9,457 | $0 |
| SG&A Expenses | $7,220 | $9,070 | $9,457 | $13,251 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$2,419 | -$3,440 | $0 |
| Operating Expenses | $45,567 | $38,926 | $35,601 | $38,922 |
| Operating Income | -$45,567 | -$41,345 | -$39,041 | -$39,026 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $3,714 | $4,391 | $4,972 | $5,708 |
| Pre-Tax Income | -$41,853 | -$36,954 | -$34,069 | -$33,318 |
| Tax Expense | $196 | $207 | $203 | $225 |
| Net Income | -$42,049 | -$37,161 | -$34,272 | -$33,543 |
| % Margin | – | – | – | – |
| EPS | -0.53 | -0.44 | -0.4 | -0.4 |
| % Growth | -20.5% | -10% | 0% | – |
| EPS Diluted | -0.53 | -0.44 | -0.4 | -0.4 |
| Weighted Avg Shares Out | 79,052 | 83,747 | 85,159 | 84,463 |
| Weighted Avg Shares Out Dil | 79,052 | 83,747 | 85,159 | 84,463 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $4,391 | $4,972 | $5,708 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $104 | $104 | $104 | $104 |
| EBITDA | -$41,749 | -$41,319 | -$38,937 | -$33,214 |
| % Margin | – | – | – | – |